LAG3: a novel immune checkpoint expressed by multiple lymphocyte subsets in diffuse large B-cell lymphoma
Top Cited Papers
Open Access
- 14 April 2020
- journal article
- research article
- Published by American Society of Hematology in Blood Advances
- Vol. 4 (7), 1367-1377
- https://doi.org/10.1182/bloodadvances.2019001390
Abstract
Blockade of the PD-1 axis has modest efficacy in diffuse large B-cell lymphoma (DLBCL), but data regarding LAG3 are sparse. The impact of LAG3 digital gene expression was tested in 309 patients with DLBCL treated with standard chemoimmunotherapy. Cellular distribution of LAG3 protein was determined by immunohistochemistry and flow cytometry. In tumorinfiltrating lymphocytes (TILs), LAG3 expression was highest on CD4(+) regulatory T cells (Tregs) and was also highly expressed on CD8(+) T cells compared with CD4(+) non-Tregs (both P = .008). LAG3(high) TILs were enriched in PD-1 and TIM-3. LAG3 was also expressed on a proportion of malignant B cells, and these patients had significantly higher LAG3 messenger RNA in their biopsies (P = .03). LAG3(high) gene expression was associated with inferior survival in discovery/validation cohorts, independent of cell of origin and the international prognostic index. Patients who were PD-L1(high) were fivefold more likely to be LAG3 hi g h (P < .0001). Patients who were LAG3(high)/PD-L1(high) had an inferior progression-free survival (P = .011) and overall survival (P = .005) compared with patients who were LAG3(low)/PD-L/(high). Digital spatial protein analysis confirms LAG3 expression on T cells and, surprisingly, tumor-associated macrophages (TAMS) at higher levels than found on CD20(+) B cells in the tumor microenvironment. LAG3 is frequently expressed on CD4(+) Tregs and CD8(+) TILs, typically with other immune checkpoints, and is also present in a proportion of malignant B cells in DLBCL and in areas enriched for TAMS. LAG3 high expression is associated with poor outcome independent of conventional prognosticators.This publication has 39 references indexed in Scilit:
- Orchestration and Prognostic Significance of Immune Checkpoints in the Microenvironment of Primary and Metastatic Renal Cell CancerClinical Cancer Research, 2015
- Several immune escape patterns in non-Hodgkin's lymphomasOncoImmunology, 2015
- Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissueBlood, 2014
- Coexpression of CD49b and LAG-3 identifies human and mouse T regulatory type 1 cellsNature Medicine, 2013
- Immune Inhibitory Molecules LAG-3 and PD-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune EscapeCancer Research, 2012
- Flow Cytometric Detection of Human Regulatory T CellsPublished by Springer Science and Business Media LLC ,2011
- Expression of LAG-3 by tumor-infiltrating lymphocytes is coincident with the suppression of latent membrane antigen–specific CD8+ T-cell function in Hodgkin lymphoma patientsBlood, 2006
- CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cellsThe Journal of Experimental Medicine, 2006
- On the exact distribution of maximally selected rank statisticsComputational Statistics & Data Analysis, 2003
- The CD4‐related molecule, LAG‐3 (CD223), regulates the expansion of activated T cellsEuropean Journal of Immunology, 2003